archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Limited today announced its first half result for period ended 31 December 2010.
    Development Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Half year results announcement for 2010 11 Half year results announcement for 2010 11 Melbourne Australia 16 02 2011 CSL Limited today announced its first half result for period ended 31 December 2010 Download this release CSL Half Year Results Announcement for 2010 11 0 1

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255925859621/prdetail.htm (2014-01-05)
    Open archived version from archive


  • Company Statement - Shelf Life Reduction of Panvax® Junior
    monitoring by both CSL and the TGA of CSL s Panvax Junior vaccine has shown a decline in its potency and as a result a 12 month shelf life can no longer be supported Panvax Junior is the paediatric presentation of CSL s 2009 H1N1 pandemic influenza vaccine which is supplied in a single 0 25ml pre filled syringe This situation is not unique Regulators and manufacturers in other countries have identified similar trends in their single dose monovalent H1N1 vaccines The decline in potency is specific to the 2009 monovalent single strain H1N1 vaccine when presented in small volumes such as Panvax Junior Panvax and other manufacturers H1N1 vaccines in multi dose vials are not affected nor are trivalent seasonal influenza vaccines that contain the H1N1 strain Based on this information and following consultation with the TGA a decision has been made to limit the shelf life of Panvax Junior to 6 months and as a result all remaining doses are now to be considered expired CSL has written to immunisation providers to inform them of this decision and will be conducting a retrieval program for all remaining doses of Panvax Junior Importantly no unexpected safety or efficacy concerns

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255924897435/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Update on Seasonal Influenza Vaccination of Children
    children Since becoming aware of an association between CSL s influenza vaccine and increased febrile reactions in children in Australia during the 2010 Southern Hemisphere influenza season CSL has worked closely with the Therapeutic Goods Administration TGA to investigate the cause In parallel with the TGA s investigations and in accordance with regulatory guidance CSL has undertaken comprehensive analyses of clinical and epidemiological data in depth reviews of manufacturing and quality processes and conducted laboratory testing of the vaccine Investigations conducted by both the authorities and CSL have excluded numerous possible causes The unexpectedly high rate of these events has not been seen in previous seasons nor following the use of our H1N1 pandemic vaccine and our manufacturing processes have not changed CSL s expert team continues to work with the TGA to identify further avenues of investigation said Dr Darryl Maher Medical and Research Director for CSL Biotherapies CSL supports a precautionary approach to the use of its influenza vaccine in children while investigations continue into the cause of the unexpected increase in febrile reactions added Dr Maher CSL recently completed its voluntary retrieval program for remaining 2010 paediatric influenza vaccine from medical clinics and distributors ensuring sufficient quantities

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255924656041/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Announces New Biotech facility
    CSL Limited today announced a major biotechnology project at CSL s manufacturing site in Broadmeadows Australia The centrepiece of the project will be the creation of Victoria s first large scale biotechnology facility for the late stage development of new therapies for cancer bleeding disorders inflammation and infection Our world class R D portfolio contains promising life saving therapies for a range of serious human diseases This new facility will enable CSL to develop innovative products for clinical trials and future patient use said CSL s CEO Dr Brian McNamee CSL s Broadmeadows site currently houses state of the art manufacturing facilities that produce a range of highly specialised medicines CSL s investment will include enhancements to the site to support the integration of the new biotech facility and to ensure it has the appropriate infrastructure to cater for expanded activities into the future The project will represent a total investment of 235M over 4 5 years and will result in 320 jobs during construction Following completion the investment will create over 330 new highly skilled positions CSL is proud to be investing in a project that will not only generate significant employment opportunities but will also have enormous spill

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255924559119/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Update on Seasonal Influenza Vaccination of Young Children
    effects in young children following this season s influenza vaccination The Chief Medical Officer subsequently advised immunisation providers to stop vaccinating children 5 years and under pending further investigation At this time CSL ceased distribution of its paediatric influenza vaccine as a precautionary measure and began urgent investigations with government and regulatory authorities Analyses of currently available data show that there has been a significant increase in reports of fever and febrile convulsion in children aged less than 5 years shortly after receiving CSL s 2010 influenza vaccine compared to previous seasons Extensive investigations conducted by the authorities and CSL to date have not established an explanation for the increase in reports of side effects In light of this information CSL has updated its prescribing information for influenza vaccine and is writing to doctors to inform them of this important update As a further precautionary measure and as part of ongoing investigations by CSL and regulatory authorities CSL has voluntarily commenced a retrieval program for its remaining 2010 paediatric influenza vaccine from medical clinics and distributors CSL supports the Chief Medical Officer s recommendation to not vaccinate healthy children under 5 with seasonal influenza vaccine this year and that doctors should conduct a careful assessment of the risk and benefits when considering vaccination for children at risk CSL has more than 40 years experience in manufacturing and testing influenza vaccine and the safety profile of our influenza vaccine has been well established The reports we have seen this season in children under 5 are unexpected and not consistent with our experience using previous seasons vaccines said Dr Darryl Maher CSL Medical and Research Director The actions taken by CSL reflect the utmost importance we place on patient safety and the quality of our products We will continue to work with

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255924331182/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Seasonal influenza vaccine – paediatric adverse events
    Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive Seasonal influenza vaccine paediatric adverse events Seasonal influenza vaccine paediatric adverse events Melbourne Australia 23 04 2010 CSL Biotherapies is aware of reports of a number of adverse events following influenza vaccination of children CSL is one of several suppliers of influenza vaccine in Australia CSL is urgently investigating these reports in association with the relevant regulatory bodies including the TGA and WA Health As a further precautionary measure and in support of the Commonwealth Chief Medical Officer s decision advising GPs and immunisation providers to stop giving seasonal influenza vaccine to children under 5 years of age CSL has taken the action to withhold further distribution of its paediatric influenza vaccine nationally to reduce the risk of inadvertent administration in this age group said Dr Darryl Maher CSL Medical and Research Director The company takes the safety and quality of its products seriously and will provide more detailed information as soon as possible Download the release Seasonal influenza vaccine paediatric adverse events 0 09Mb Media Contact Jo Lynch Hinton Associates Phone 61 3 9600 1979 Mobile 61 411

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255923958227/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL subsidiary marks World Hemophilia Day with Factor IX Donation
    News Alert Search News by Date Contact CSL Home Newsroom News Archive CSL subsidiary Marks World Hemophilia Day with Factor IX Donation to World Federation of Hemophilia CSL subsidiary Marks World Hemophilia Day with Factor IX Donation to World Federation of Hemophilia King of Prussia PA and Montreal Canada 16 04 2010 Hemophilia B patients in the developing world will benefit from a recent donation of 1 million international units

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255923921468/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited publishes first Corporate Responsibility Report
    Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive CSL Limited publishes first Corporate Responsibility Report CSL Limited publishes first Corporate Responsibility Report Melbourne Australia 30 03 2010 CSL Limited ASX CSL Australia s leading biopharmaceutical company has released its first Corporate Responsibility Report combining information about the Company s economic social and environmental performance for 2009 CSL has experienced significant growth over the past 10 years which has been underpinned by our commitment to conducting our business ethically and actively contributing to the well being of our communities said Dr Brian McNamee CEO and Managing Director of CSL Limited Our first Corporate Responsibility Report is an important demonstration of this ongoing commitment The report details CSL s approach to and performance in key areas of corporate responsibility These include the Company s research into new medicines its ongoing success in ensuring the safety and quality of its broad portfolio of therapies providing a positive and healthy work environment for CSL employees behaving responsibly in the global marketplace and providing charitable support for communities in need around the world while minimising the environmental impacts of its operations Additional Resources Visit the

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255923818998/prdetail.htm (2014-01-05)
    Open archived version from archive